Primary Myelofibrosis Terminated Phase 2 Trials for Ruxolitinib (DB08877)

Also known as: Myelofibrosis, Primary / Osteomyelofibrosis / Chronic idiopathic myelofibrosis

IndicationStatusPhase
DBCOND0001581 (Primary Myelofibrosis)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02091752A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)Treatment